These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23480103)

  • 1. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system.
    Johnson L; Loh YS; Kwok M; Marks DC
    Transfus Med; 2013 Apr; 23(2):121-9. PubMed ID: 23480103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™).
    Chavarin P; Cognasse F; Argaud C; Vidal M; De Putter C; Boussoulade F; Ripaud C; Acquart S; Lin L; Garraud O
    Vox Sang; 2011 Feb; 100(2):247-9. PubMed ID: 20735811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
    Picker SM; Oustianskaia L; Schneider V; Gathof BS
    Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover.
    Johnson L; Winter KM; Reid S; Hartkopf-Theis T; Marschner S; Goodrich RP; Marks DC
    Vox Sang; 2011 Oct; 101(3):208-14. PubMed ID: 21492184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.
    Hechler B; Ohlmann P; Chafey P; Ravanat C; Eckly A; Maurer E; Mangin P; Isola H; Cazenave JP; Gachet C
    Transfusion; 2013 Jun; 53(6):1187-200. PubMed ID: 23067365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
    Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
    Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryopreservation of buffy-coat-derived platelet concentrates in dimethyl sulfoxide and platelet additive solution.
    Johnson LN; Winter KM; Reid S; Hartkopf-Theis T; Marks DC
    Cryobiology; 2011 Apr; 62(2):100-6. PubMed ID: 21241687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology.
    Ostrowski SR; Bochsen L; Salado-Jimena JA; Ullum H; Reynaerts I; Goodrich RP; Johansson PI
    Transfusion; 2010 Oct; 50(10):2210-9. PubMed ID: 20456708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized processing for pathogen inactivation of double-dose buffy-coat platelet concentrates: maintained in vitro quality over 7-day storage.
    Ohlsson S; Diedrich B; Uhlin M; Sandgren P
    Vox Sang; 2018 Oct; 113(7):611-621. PubMed ID: 30156292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light.
    Wagner SJ; Skripchenko A; Myrup A; Awatefe H; Thompson-Montgomery D; Moroff G; Carmichael P; Lin L
    Transfusion; 2009 Apr; 49(4):704-10. PubMed ID: 19171001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended storage of platelets in SSP platelet additive solution.
    Hornsey VS; McColl K; Drummond O; McMillan L; Morrison A; Morrison L; MacGregor IR; Prowse CV
    Vox Sang; 2006 Jul; 91(1):41-6. PubMed ID: 16756600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro storage characteristics of platelet concentrates suspended in 70% SSP+(TM) additive solution versus plasma over a 14-day storage period.
    Saunders C; Rowe G; Wilkins K; Holme S; Collins P
    Vox Sang; 2011 Aug; 101(2):112-21. PubMed ID: 21414010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.
    Reikvam H; Marschner S; Apelseth TO; Goodrich R; Hervig T
    Blood Transfus; 2010 Jul; 8(3):186-92. PubMed ID: 20671879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method.
    Sandgren P; Tolksdorf F; Struff WG; Gulliksson H
    Vox Sang; 2011 Jul; 101(1):35-43. PubMed ID: 21175668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
    Tauszig ME; Picker SM; Gathof BS
    Transfus Apher Sci; 2012 Feb; 46(1):33-7. PubMed ID: 22119364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of procoagulant collagen- and thrombin-activated platelets in platelet concentrates derived from buffy coat: the role of processing, pathogen inactivation, and storage.
    Bertaggia Calderara D; Crettaz D; Aliotta A; Barelli S; Tissot JD; Prudent M; Alberio L
    Transfusion; 2018 Oct; 58(10):2395-2406. PubMed ID: 30229925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Storage of buffy-coat-derived platelets in additive solutions at 4 degrees C and 22 degrees C: flow cytometry analysis of platelet glycoprotein expression.
    Sandgren P; Hansson M; Gulliksson H; Shanwell A
    Vox Sang; 2007 Jul; 93(1):27-36. PubMed ID: 17547562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function.
    Sandgren P; Diedrich B
    Vox Sang; 2015 May; 108(4):340-9. PubMed ID: 25557354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolomic analysis of platelets during storage: a comparison between apheresis- and buffy coat-derived platelet concentrates.
    Paglia G; Sigurjónsson ÓE; Rolfsson Ó; Hansen MB; Brynjólfsson S; Gudmundsson S; Palsson BO
    Transfusion; 2015 Feb; 55(2):301-13. PubMed ID: 25156572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet storage lesion in interim platelet unit concentrates: A comparison with buffy-coat and apheresis concentrates.
    Singh S; Shams Hakimi C; Jeppsson A; Hesse C
    Transfus Apher Sci; 2017 Dec; 56(6):870-874. PubMed ID: 29126740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.